Fan Lai
Research Subjects
Fan Lai has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Ao Dong
Yunnan University
1 shared publication- Haixue Zheng
State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences
1 shared publication Hongbin Jia
State Key Laboratory of Applied Organic Chemistry, Department of Chemistry and School of Pharmacy, Lanzhou University
1 shared publicationJun Han
State Key Laboratory of Applied Organic Chemistry, Department of Chemistry and School of Pharmacy, Lanzhou University
1 shared publicationLingzhi Li
Yunnan University
1 shared publicationQiong Tian
State Key Laboratory of Applied Organic Chemistry, Department of Chemistry and School of Pharmacy, Lanzhou University
1 shared publication
Latest Publications
- Open Access
- 9 January 2024
- Published by Springer Nature in Research Square
Orally Available Small Molecule Regulates TXNIP Expression and Glucagon Action for the Treatment of Diabetes
In the progression of diabetes, sustained glucagon secretion facilitates glucose production. Despite its significance, no treatments currently target this vital parameter. We employed the promoter sequence of thioredoxin-interacting protein (TXNIP) as a screening target, evaluated our in-house chemical library, and subsequently undertook high-throughput screening and optimization via various medicinal chemistry techniques. Our efforts led to the identification of SKL-1223, an orally administered, non-toxic small molecule capable of effectively regulating blood glucose levels in both streptozotocin-induced and obesity-induced (db/db) diabetic mice. Furthermore, our study elucidated the hypoglycemic effect of glucagon and its role in reducing hepatic glucose output. On a mechanistic level, SKL-1223 interacts with the E-box region of the TXNIP promoter, consequently suppressing TXNIP transcription and associated signaling pathways. Thus, our study introduces a novel compound, offering a fresh therapeutic avenue for diabetes beyond existing regimens.
- 9 January 2024
- Published by Springer Nature in Research Square
Open AccessOrally Available Small Molecule Regulates TXNIP Expression and Glucagon Action for the Treatment of Diabetes
In the progression of diabetes, sustained glucagon secretion facilitates glucose production. Despite its significance, no treatments currently target this vital parameter. We employed the promoter sequence of thioredoxin-interacting protein (TXNIP) as a screening target, evaluated our in-house chemical library, and subsequently undertook high-throughput screening and optimization via various medicinal chemistry techniques. Our efforts led to the identification of SKL-1223, an orally administered, non-toxic small molecule capable of effectively regulating blood glucose levels in both streptozotocin-induced and obesity-induced (db/db) diabetic mice. Furthermore, our study elucidated the hypoglycemic effect of glucagon and its role in reducing hepatic glucose output. On a mechanistic level, SKL-1223 interacts with the E-box region of the TXNIP promoter, consequently suppressing TXNIP transcription and associated signaling pathways. Thus, our study introduces a novel compound, offering a fresh therapeutic avenue for diabetes beyond existing regimens.